Travis Steed
Stock Analyst at B of A Securities
(2.76)
# 1,786
Out of 5,127 analysts
91
Total ratings
46.48%
Success rate
6.62%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBNX Beta Bionics | Maintains: Buy | $30 → $33 | $31.99 | +3.16% | 1 | Jan 5, 2026 | |
| PEN Penumbra | Maintains: Buy | $320 → $370 | $315.54 | +17.26% | 2 | Jan 5, 2026 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $207 | $205.18 | +0.89% | 10 | Jan 5, 2026 | |
| CNMD CONMED | Maintains: Neutral | $65 → $52 | $44.20 | +17.65% | 5 | Dec 8, 2025 | |
| MASI Masimo | Initiates: Neutral | $162 | $137.91 | +17.47% | 1 | Nov 17, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $126.18 | +18.88% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $85.77 | -0.90% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $84.58 | +6.41% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $23.07 | +38.71% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $20.69 | +117.50% | 5 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $480 → $45 | $4.67 | +863.60% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $315 | $367.21 | -14.22% | 5 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $295 | $292.89 | +0.72% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $33.37 | -52.05% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $22.50 | +46.67% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $94.08 | +70.07% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $585.08 | -46.16% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $2.10 | +280.95% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $12.76 | +95.92% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.26 | +496.07% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $68.43 | +82.67% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $98.69 | +46.92% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $98.38 | -48.16% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $13.86 | +289.61% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $67.85 | -67.58% | 1 | Jul 17, 2017 |
Beta Bionics
Jan 5, 2026
Maintains: Buy
Price Target: $30 → $33
Current: $31.99
Upside: +3.16%
Penumbra
Jan 5, 2026
Maintains: Buy
Price Target: $320 → $370
Current: $315.54
Upside: +17.26%
Becton, Dickinson and Company
Jan 5, 2026
Maintains: Neutral
Price Target: $190 → $207
Current: $205.18
Upside: +0.89%
CONMED
Dec 8, 2025
Maintains: Neutral
Price Target: $65 → $52
Current: $44.20
Upside: +17.65%
Masimo
Nov 17, 2025
Initiates: Neutral
Price Target: $162
Current: $137.91
Upside: +17.47%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $126.18
Upside: +18.88%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $85.77
Upside: -0.90%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $84.58
Upside: +6.41%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $23.07
Upside: +38.71%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $20.69
Upside: +117.50%
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $4.67
Upside: +863.60%
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $367.21
Upside: -14.22%
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $292.89
Upside: +0.72%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $33.37
Upside: -52.05%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $22.50
Upside: +46.67%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $94.08
Upside: +70.07%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $585.08
Upside: -46.16%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $2.10
Upside: +280.95%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $12.76
Upside: +95.92%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.26
Upside: +496.07%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $68.43
Upside: +82.67%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $98.69
Upside: +46.92%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $98.38
Upside: -48.16%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $13.86
Upside: +289.61%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $67.85
Upside: -67.58%